These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 34961704)
1. Impact of Variant Histology on Occult Nodal Metastasis after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Review of the National Cancer Database. Fu M; Klose C; Sparks A; Whalen M Clin Genitourin Cancer; 2022 Apr; 20(2):e135-e139. PubMed ID: 34961704 [TBL] [Abstract][Full Text] [Related]
2. Impact of Neoadjuvant Chemotherapy on Pathologic Downstaging in Patients With Variant Histology Undergoing Radical Cystectomy. Campbell RA; Khanna A; Boorjian SA; Knorr J; Cox R; Nicholas M; Cheville J; Sharma V; Murthy PB; Tarrell R; Thapa P; Tollefson MK; Thompson RH; Frank I; Karnes RJ; Haber GP; Lee B Clin Genitourin Cancer; 2024 Apr; 22(2):157-163.e1. PubMed ID: 38008690 [TBL] [Abstract][Full Text] [Related]
3. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503 [TBL] [Abstract][Full Text] [Related]
4. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. Rahman SN; Lokeshwar SD; Syed JS; Javier-Desloges JF; Press BH; Choksi AU; Rajwa P; Pradere B; Ploussard G; Kim JW; Monaghan TF; Renzulli JR; Shariat SF; Leapman MS Urol Oncol; 2023 Feb; 41(2):107.e1-107.e8. PubMed ID: 36481253 [TBL] [Abstract][Full Text] [Related]
5. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387 [TBL] [Abstract][Full Text] [Related]
6. Occult Nodal Metastases in Patients Down-Staged to Nonmuscle Invasive Disease Following Neoadjuvant Chemotherapy. Nassiri N; Ghodoussipour S; Maas M; Nazemi A; Asanad K; Pearce S; Bhanvadia SS; Djaladat H; Schuckman A; Daneshmand S Urology; 2020 Aug; 142():155-160. PubMed ID: 32268173 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155 [TBL] [Abstract][Full Text] [Related]
8. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296 [TBL] [Abstract][Full Text] [Related]
9. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients. van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718 [TBL] [Abstract][Full Text] [Related]
11. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU; Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383 [TBL] [Abstract][Full Text] [Related]
12. The role of neoadjuvant chemotherapy for patients with variant histology muscle invasive bladder cancer undergoing robotic cystectomy: Data from the International Robotic Cystectomy Consortium. Cooke I; Abou Heidar N; Mahmood AW; Ahmad A; Jing Z; Stöckle M; Wagner AA; Roupret M; Kim E; Vasdev N; Balbay D; Rha KH; Aboumohamed A; Dasgupta P; Maatman TJ; Richstone L; Wiklund P; Gaboardi F; Li Q; Hussein AA; Guru K Urol Oncol; 2024 Apr; 42(4):117.e17-117.e25. PubMed ID: 38429124 [TBL] [Abstract][Full Text] [Related]
13. Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy. McFadden J; Tachibana I; Adra N; Collins K; Cary C; Koch M; Kaimakliotis H; Masterson TA; Rice KR Urol Oncol; 2024 Mar; 42(3):69.e11-69.e16. PubMed ID: 38267301 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Hanna N; Trinh QD; Seisen T; Vetterlein MW; Sammon J; Preston MA; Lipsitz SR; Bellmunt J; Menon M; Choueiri TK; Abdollah F Eur Urol Oncol; 2018 May; 1(1):83-90. PubMed ID: 31100232 [TBL] [Abstract][Full Text] [Related]
15. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone. Mertens LS; Meijer RP; Meinhardt W; van der Poel HG; Bex A; Kerst JM; van der Heijden MS; Bergman AM; Horenblas S; van Rhijn BW BJU Int; 2014 Jul; 114(1):67-74. PubMed ID: 24053889 [TBL] [Abstract][Full Text] [Related]
16. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364 [TBL] [Abstract][Full Text] [Related]
17. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489 [TBL] [Abstract][Full Text] [Related]
18. Trends in Treatment Strategies and Comparison of Outcomes in Lymph Node Positive Bladder Cancer: An Analysis of the National Cancer Database. Darwish C; Sparks A; Amdur R; Reddy A; Whalen M Urology; 2020 Dec; 146():168-176. PubMed ID: 32866509 [TBL] [Abstract][Full Text] [Related]
19. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder. Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614 [TBL] [Abstract][Full Text] [Related]
20. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]